東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Regulating pharmaceutical prices in ...

Bhaskarabhatla, Ajay.

FindBook

Google Book

Amazon

博客來

Regulating pharmaceutical prices in India = policy design, implementation and compliance /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Regulating pharmaceutical prices in India/ by Ajay Bhaskarabhatla.
其他題名:	policy design, implementation and compliance /
作者:	Bhaskarabhatla, Ajay.
出版者:	Cham :Springer International Publishing : : 2018.,
面頁冊數:	ix, 306 p. :digital ;24 cm.
內容註:	Introduction -- Part I. Historical Context and the Motivation for Regulation -- Brief History of Regulating Pharmaceutical Prices -- Is the 2013 Price Control Regulation Necessary? -- Part II. The Design of the 2013 DPCO Regulation -- The Proposed Design to Fix Ceiling Prices Under 2013 DPCO -- Challenges with Fixing the Ceiling Price Under the 2013 DPCO -- Part III. The Impact of the 2013 DPCO -- How Effective Are the 2013 DPCO Regulations? -- Firm Strategies to Mitigate the Impact of Price Control Regulation -- Part IV. Enforcement and Compliance -- Enforcement and Compliance with Price Ceilings on Essential Medicines -- Conclusion.
Contained By:	Springer eBooks
標題:	Drugs - Prices - India. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-93393-1
ISBN:	9783319933931

Regulating pharmaceutical prices in India = policy design, implementation and compliance /
Bhaskarabhatla, Ajay.

Regulating pharmaceutical prices in Indiapolicy design, implementation and compliance /[electronic resource] :by Ajay Bhaskarabhatla. - Cham :Springer International Publishing :2018. - ix, 306 p. :digital ;24 cm. - India studies in business and economics,2198-0012. - India studies in business and economics..

Introduction -- Part I. Historical Context and the Motivation for Regulation -- Brief History of Regulating Pharmaceutical Prices -- Is the 2013 Price Control Regulation Necessary? -- Part II. The Design of the 2013 DPCO Regulation -- The Proposed Design to Fix Ceiling Prices Under 2013 DPCO -- Challenges with Fixing the Ceiling Price Under the 2013 DPCO -- Part III. The Impact of the 2013 DPCO -- How Effective Are the 2013 DPCO Regulations? -- Firm Strategies to Mitigate the Impact of Price Control Regulation -- Part IV. Enforcement and Compliance -- Enforcement and Compliance with Price Ceilings on Essential Medicines -- Conclusion.

This book presents an extensive study on the effectiveness of recent regulations on pharmaceutical prices in India, exploring the weaknesses in the design and implementation of pharmaceutical price controls and investigating what can be done to fix the broken system. In addition, it examines the extent to which essential medicines are actually made affordable by price controls. The book argues that companies make the pharmaceutical price control regime largely ineffective by coordinating to increase pre-regulation prices; by diversifying horizontally away from the regulated markets and increasing prices in the unregulated markets; by manipulating trade margins; and by refusing to comply with the regulation because the penalties remains negligible. The book draws on extensive empirical research involving India's 2013 Drug Price Control Order and widely-used medicines such as paracetamol and metformin to illustrate how firms have weakened regulation. It argues that the regulatory regime can be strengthened by using systematic analysis of product- and region-level data in the Indian pharmaceutical industry, and by screening for the strategies that firms currently employ to circumvent regulation. In closing, it discusses recent efforts to strengthen the implementation of price controls in India and expanding the scope of price controls to medical devices.

ISBN: 9783319933931

Standard No.: 10.1007/978-3-319-93393-1doiSubjects--Topical Terms:

3338446
Drugs
--Prices--India.

LC Class. No.: KNS863

Dewey Class. No.: 343.54078338476151

Regulating pharmaceutical prices in India = policy design, implementation and compliance /
LDR:03056nmm a2200325 a 4500 001 2152286
003 DE-He213
005 20190123140631.0
006 m d
007 cr nn 008maaau
008 190403s2018 gw s 0 eng d
020 $a 9783319933931 $q (electronic bk.)
020 $a 9783319933924 $q (paper)
024 7 $a 10.1007/978-3-319-93393-1 $2 doi
035 $a 978-3-319-93393-1
040 $a GP $c GP
041 0 $a eng
050 4 $a KNS863
072 7 $a KCQ $2 bicssc
072 7 $a BUS069000 $2 bisacsh
082 0 4 $a 343.54078338476151 $2 23
090 $a KNS863 $b .B575 2018
100 1 $a Bhaskarabhatla, Ajay. $3 3338445
245 1 0 $a Regulating pharmaceutical prices in India $h [electronic resource] : $b policy design, implementation and compliance / $c by Ajay Bhaskarabhatla.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a ix, 306 p. : $b digital ; $c 24 cm.
490 1 $a India studies in business and economics, $x 2198-0012
505 0 $a Introduction -- Part I. Historical Context and the Motivation for Regulation -- Brief History of Regulating Pharmaceutical Prices -- Is the 2013 Price Control Regulation Necessary? -- Part II. The Design of the 2013 DPCO Regulation -- The Proposed Design to Fix Ceiling Prices Under 2013 DPCO -- Challenges with Fixing the Ceiling Price Under the 2013 DPCO -- Part III. The Impact of the 2013 DPCO -- How Effective Are the 2013 DPCO Regulations? -- Firm Strategies to Mitigate the Impact of Price Control Regulation -- Part IV. Enforcement and Compliance -- Enforcement and Compliance with Price Ceilings on Essential Medicines -- Conclusion.
520 $a This book presents an extensive study on the effectiveness of recent regulations on pharmaceutical prices in India, exploring the weaknesses in the design and implementation of pharmaceutical price controls and investigating what can be done to fix the broken system. In addition, it examines the extent to which essential medicines are actually made affordable by price controls. The book argues that companies make the pharmaceutical price control regime largely ineffective by coordinating to increase pre-regulation prices; by diversifying horizontally away from the regulated markets and increasing prices in the unregulated markets; by manipulating trade margins; and by refusing to comply with the regulation because the penalties remains negligible. The book draws on extensive empirical research involving India's 2013 Drug Price Control Order and widely-used medicines such as paracetamol and metformin to illustrate how firms have weakened regulation. It argues that the regulatory regime can be strengthened by using systematic analysis of product- and region-level data in the Indian pharmaceutical industry, and by screening for the strategies that firms currently employ to circumvent regulation. In closing, it discusses recent efforts to strengthen the implementation of price controls in India and expanding the scope of price controls to medical devices.
650 0 $a Drugs $x Prices $x Law and legislation $z India. $3 3338446
650 1 4 $a Economics. $3 517137
650 2 4 $a Health Economics. $3 820895
650 2 4 $a Emerging Markets/Globalization. $3 1565823
650 2 4 $a Pharmacoeconomics and Health Outcomes. $3 2089175
650 2 4 $a Political Economy/Economic Policy. $3 3250570
650 2 4 $a Development Economics. $3 894104
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a India studies in business and economics. $3 2054979
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-93393-1
950 $a Economics and Finance (Springer-41170)